The below Parliamentary question was asked by John Glen on 2016-02-22.
To ask the Secretary of State for Health, if NHS England will publish a list of the commissioning policies scheduled to be developed in (a) 2015-16, (b) 2016-17 and (c) 2017-18.
George Freeman
There are no plans for NHS England to publish the list of clinical policies in development.
The below Parliamentary question was asked by John Glen on 2016-07-12.
To ask the Secretary of State for Communities and Local Government, what recent assessment he has made of the effectiveness of the introduction of the English language tuition scheme in supporting Muslim women to learn English.
Mr Marcus Jones
As the first step in rolling out the new £20 million programme we have committed just over £3 million to enable six providers who delivered the Department’s previous community-based English language programme to provide new tuition to over 10,000 people by March next year.
We will shortly be issuing a new Prospectus, inviting applications to run the bulk of the new programme from 2017. The nature and targeting of that provision will be informed by Louise Casey’s Review of Integration and Opportunity.
We will monitor the new Programme to assess its effectiveness in meeting its objectives.
The below Parliamentary question was asked by John Glen on 2016-02-22.
To ask the Secretary of State for Health, if NHS England will publish the (a) agendas and (b) minutes of all future meetings of the (i) Clinical Advisory Group and (ii) Specialised Commissioning Committee within a reasonable period after each such meeting takes place.
George Freeman
The specialised services commissioning committee provides regular updates of its business to NHS England’s public board, of which a summary is published online.
NHS England is considering how to further improve transparency, while not inhibiting the free and frank exchange of views.
The below Parliamentary question was asked by John Glen on 2016-07-12.
To ask the Secretary of State for Communities and Local Government, how many women have received tuition under the English language tuition scheme since January 2016.
Mr Marcus Jones
As the first step in rolling out the new £20 million programme we have committed just over £3 million to enable six providers who delivered the Department’s previous community-based English language programme to provide new tuition to over 10,000 people by March next year.
We will shortly be issuing a new Prospectus, inviting applications to run the bulk of the new programme from 2017. The nature and targeting of that provision will be informed by Louise Casey’s Review of Integration and Opportunity.
We will monitor the new Programme to assess its effectiveness in meeting its objectives.
The below Parliamentary question was asked by John Glen on 2016-02-29.
To ask the Minister for the Cabinet Office, how many people died from liver disease in (a) England and (b) each parliamentary constituency in the most recent year for which figures are available.
Mr Rob Wilson
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
The below Parliamentary question was asked by John Glen on 2016-07-12.
To ask the Secretary of State for Communities and Local Government, how much of the English language tuition fund his Department has spent since January 2016.
Mr Marcus Jones
As the first step in rolling out the new £20 million programme we have committed just over £3 million to enable six providers who delivered the Department’s previous community-based English language programme to provide new tuition to over 10,000 people by March next year.
We will shortly be issuing a new Prospectus, inviting applications to run the bulk of the new programme from 2017. The nature and targeting of that provision will be informed by Louise Casey’s Review of Integration and Opportunity.
We will monitor the new Programme to assess its effectiveness in meeting its objectives.
The below Parliamentary question was asked by John Glen on 2015-10-20.
To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, what assessment his Department has made of the date on which he will issue a tender for extended half-life products.
George Freeman
The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.
NHS England has made no decision to develop a clinical commissioning policy for ‘extended half-life products’. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.
The below Parliamentary question was asked by John Glen on 2015-10-20.
To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, when NHS England plans to take a decision on the development of a clinical commissioning policy for extended half-life products; what discussions NHS England has had to date on such a clinical commissioning policy; and if he will make a statement.
George Freeman
The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.
NHS England has made no decision to develop a clinical commissioning policy for ‘extended half-life products’. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.
The statement made by John Glen, the Chief Secretary to the Treasury, in the House of Commons on 17 November 2022.
The Tax Credits Act 2002 and the Social Security Administration Act 1992 place a statutory duty on His Majesty’s Treasury to review the rates of tax credits and child benefit each year in line with the general level of prices. There is a further statutory duty on the Treasury to increase guardian’s allowance in line with price growth. I have now concluded the review for the tax year 2023-24.
I have decided to increase tax credits and child benefit rates in line with the consumer price index (CPI) for the year to September 2022. Guardian’s allowance will also increase by the same rate. This means that:
The majority of elements and thresholds in working tax credit and child tax credit, including all disability elements, will increase by 10.1% from 6 April 2023. This means, for example, that the basic element of working tax credit will increase from £2,070 to £2,280 per year. In line with established practice and the Office for Budget Responsibility’s expectations in their welfare forecast, the maximum rate of the childcare element, the family element, the withdrawal rate and disregards in tax credits will remain unchanged.
All rates of child benefit, plus guardian’s allowance, will increase by 10.1 % from 10 April 2023. This means, for example, that the child benefit rate for the eldest child will increase from £21.80 to £24 per week.
The new rates will apply across the United Kingdom. I will deposit the full list of these rates in the Libraries of both Houses shortly.
The below Parliamentary question was asked by John Glen on 2015-10-09.
To ask the Secretary of State for Health, what plans he has to procure extended half-life blood clotting factor products for use in the NHS.
George Freeman
The Department plans to tender for extended half-life Clotting Factor VIII and Factor IX for use in the National Health Service once the products are granted European Union licences and are commercially available.
NHS England has made no decision at this time to whether it will develop a clinical commissioning policy for extended half-life productsbut, through the Clinical Reference Group and discussion with the Department’s Commercial Medicines Unit, will continue to review commissioning of these extended half-life products in the future.